Background: Increasing evidence suggests that beyond its antiplatelet properties, dipyridamole may have pleiotropic effects on other cells within the neurovascular elements of the brain. In this experimental cellular study, we asked whether dipyridamole can ameliorate brain endothelial injury after exposure to inflammatory and metabolic insults. Methods: Human brain endothelial cells were grown in culture, and exposed to TNFα (continuously for 20 h) or subjected to oxygen-glucose deprivation (OGD; 6 h of insult followed by 18 h recovery). Expression of ICAM-1, VCAM-1 and PECAM-1 were measured by immunoblotting. Matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in the conditioned media were quantified via zymography. MTT mitochondrial activity was measured to assess endothelial cell viability. Results: Exposure of human brain endothelial cells to TNFα (12.5–50 ng/ml) induced a clear increase in protein levels of ICAM-1, VCAM-1 and MMP-9. TNFα did not alter PECAM-1. Dipyridamole (1–5 µM) significantly attenuated ICAM-1 and MMP-9 levels after this inflammatory insult. No significant effects of dipyridamole were noted for VCAM-1. Six-hour OGD induced moderate endothelial cell death accompanied by a release of MMP-9. Dipyridamole significantly decreased MMP-9 levels and cell death after this metabolic insult. Conclusions: These results suggest that dipyridamole may ameliorate brain endothelial injury after inflammation and/or metabolic insults. How these putative cellular mechanisms may relate to clinical outcomes and conditions in stroke patients remains to be elucidated.

Keywords:
Inflammation, Blood-brain barrier, Stroke, Neurovascular
1.
Chakrabarti S, Freedman JE: Dipyridamole, cerebrovascular disease, and the vasculature. Vascul Pharmacol 2008;48:143–149.
2.
Bousser MG: Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc Dis 2009;27(suppl 3):12–19.
3.
Kim HH, Liao JK: Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol 2008;28:s39–s42.
4.
Weyrich AS, Denis MM, Kuhlmann-Eyre JR, Spencer ED, Dixon DA, Marathe GK, et al: Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005;111:633–642.
5.
Chen TH, Kao YC, Chen BC, Chen CH, Chan P, Lee HM: Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells. Eur J Pharmacol 2006;541:138–146.
6.
Hallevi H, Hazan-Halevy I, Paran E: Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. Eur J Neurol 2007;14:1002–1007.
7.
Chakrabarti S, Blair P, Wu C, Freedman JE: Redox state of dipyridamole is a critical determinant for its beneficial antioxidant and antiinflammatory effects. J Cardiovasc Pharmacol 2007;50:449–457.
8.
Callahan MK, Williams KA, Kivisakk P, Pearce D, Stins MF, Ransohoff RM: CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J Neuroimmunol 2004;153:150–157.
9.
Arai K, Lo EH: An oligovascular niche: cerebral endothelial cells promote the survival and proliferation of oligodendrocyte precursor cells. J Neurosci 2009;29:4351–4355.
10.
Lee SR, Lo EH: Induction of caspase-mediated cell death by matrix metalloproteinases in cerebral endothelial cells after hypoxia-reoxygenation. J Cereb Blood Flow Metab 2004;24:720–727.
11.
Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, et al: Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003;9:1313–1317.
12.
Twentyman PR, Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987;56:279–285.
13.
Castillo J, Rodriguez I: Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004;17(suppl 1):7–18.
14.
Fatar M, Stroick M, Griebe M, Hennerici M: Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 2005;20:141–151.
15.
Franzen B, Duvefelt K, Jonsson C, Engelhardt B, Ottervald J, Wickman M, et al: Gene and protein expression profiling of human cerebral endothelial cells activated with tumor necrosis factor-alpha. Brain Res Mol Brain Res 2003;115:130–146.
16.
Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW: Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 1993;296(part 3):803–809.
17.
Siminiak T, Smielecki J, Rzezniczak J, Kazmierczak M, Kalawski R, Wysocki H: The effects of dipyridamole stress test on plasma levels of soluble adhesion molecules intracellular adhesion molecule-1, vascular cell adhesion molecule-1, E-selectin and L-selectin in patients with ischemic heart disease and patients with syndrome X. Coron Artery Dis 1999;10:235–240.
18.
Nelimarkka LO, Nikkari ST, Ravanti LS, Kahari VM, Jarvelainen HT: Collagenase-1, stromelysin-1 and 92 kDa gelatinase are associated with tumor necrosis factor-alpha induced morphological change of human endothelial cells in vitro. Matrix Biol 1998;17:293–304.
19.
Zeni P, Doepker E, Schulze-Topphoff U, Huewel S, Tenenbaum T, Galla HJ: MMPs contribute to TNF-alpha-induced alteration of the blood-cerebrospinal fluid barrier in vitro. Am J Physiol Cell Physiol 2007;293:C855–C864.
20.
Amantea D, Nappi G, Bernardi G, Bagetta G, Corasaniti MT: Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J 2009;276:13–26.
21.
del Zoppo GJ: Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience 2009;158:972–982.
22.
Frijns CJ, Kappelle LJ: Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 2002;33:2115–2122.
23.
Stanimirovic D, Shapiro A, Wong J, Hutchison J, Durkin J: The induction of ICAM-1 in human cerebromicrovascular endothelial cells (HCEC) by ischemia-like conditions promotes enhanced neutrophil/HCEC adhesion. J Neuroimmunol 1997;76:193–205.
24.
Rosell A, Lo EH: Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008;8:82–89.
25.
Zhao BQ, Tejima E, Lo EH: Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007;38:748–752.
26.
Svedin P, Hagberg H, Savman K, Zhu C, Mallard C: Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci 2007;27:1511–1518.
27.
Connolly ES Jr, Winfree CJ, Springer TA, Naka Y, Liao H, Yan SD, et al: Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion: role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996;97:209–216.
28.
Soriano SG, Lipton SA, Wang YF, Xiao M, Springer TA, Gutierrez-Ramos JC, et al: Intercellular adhesion molecule-1-deficient mice are less susceptible to cerebral ischemia-reperfusion injury. Ann Neurol 1996;39:618–624.
29.
Zhang RL, Chopp M, Li Y, Zaloga C, Jiang N, Jones ML, et al: Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 1994;44:1747–1751.
30.
Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, et al: Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001;21:7724–7732.
31.
Leonardo CC, Hall AA, Collier LA, Gottschall PE, Pennypacker KR: Inhibition of gelatinase activity reduces neural injury in an ex vivo model of hypoxia-ischemia. Neuroscience 2009;160:755–766.
32.
Yang MZ, Mun CH, Choi YJ, Baik JH, Park KA, Lee WT, et al: Agmatine inhibits matrix metalloproteinase-9 via endothelial nitric oxide synthase in cerebral endothelial cells. Neurol Res 2007;29:749–754.
33.
Kim HH, Sawada N, Soydan G, Lee HS, Zhou Z, Hwang SK, et al: Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab 2008;28:1285–1293.
34.
Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13.
35.
Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665–1673.
36.
Verro P, Gorelick PB, Nguyen D: Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008;39:1358–1363.
37.
Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al: Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008;7:875–884.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.